Table 2.
Demographics of allogeneic HCT recipients
| Demographic | Data | |
|---|---|---|
| Total | 263 | |
| Median follow-up (IQR), mo | 16.0 (6.9-30.1) | |
| Mean age (range), y | 60.0 (21.7-78.4) | |
| HCT-CI | ||
| 0-1 | 80 (30) | |
| 2 | 43 (16) | |
| 3+ | 140 (53) | |
| Conditioning | ||
| Ablative | 173 (66) | |
| Reduced or nonmyeloablative | 90 (34) | |
| Diagnosis | ||
| AML | 167 (63) | |
| MDS | 96 (37) | |
| HLA match | ||
| 8/8 | 248 (94) | |
| 7/8 | 15 (6) | |
| GVHD prophylaxis | ||
| CD34+ selection | 121 (46.0) | |
| Calcineurin inhibitor based | 142 (54.0) | |
| Refined disease risk index | ||
| Low/intermediate | 142 (54.0) | |
| High | 91 (34.6) | |
| Very high | 30 (11.4) | |
Data are number of patients (percentage of total transplant recipients), unless otherwise stated.